Should organs from hepatitis C‐positive donors be used in hepatitis C‐negative recipients for liver transplantation?

Nazia Selzner, Marina Berenguer – 6 April 2018 – Given the scarcity of donated organs and the frequency of death on the waiting list, strategies that could improve the available supply of high‐quality liver grafts are much needed. Direct‐acting antiviral agent (DAA) regimens have proved to be highly effective to treat hepatitis C virus (HCV), even in the setting of posttransplantation. The question arises as to whether transplant communities should consider the utilization of HCV‐positive donors into HCV‐negative recipients.

Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation

Samarth S. Patel, Luis A. Guzman, Fei‐Pi Lin, Taylor Pence, Trevor Reichman, Binu John, Francesco S. Celi, Erika Liptrap, Chandra Bhati, Mohammad S. Siddiqui – 6 April 2018 – Coronary artery disease (CAD) assessment is a vital part of liver transplantation (LT) evaluation, as it allows for identification and medical optimization prior to transplantation. Although aspirin and statins are standard of care for CAD, they are not universally used in cirrhosis due to concerns about adverse events.

Longterm Analysis of Biliary Complications After Duct‐to‐Duct Biliary Reconstruction in Living Donor Liver Transplantations

Sung Yeon Hong, Xu‐Guang Hu, Hyun Young Lee, Je Hwan Won, Jin Woo Kim, Xue‐Yin Shen, Hee‐Jung Wang, Bong‐Wan Kim – 6 April 2018 – Biliary complication (BC) is still regarded as the Achilles’ heel of a living donor liver transplantation (LDLT). This study aims to evaluate the longterm outcomes of the duct‐to‐duct (DD) biliary reconstruction using 7‐0 suture and to identify the risk factors of BCs after LDLTs. Data of 140 LDLTs between 2006 and 2015 were analyzed.

Subscribe to